RAFT-derived polymer-drug conjugates: poly(hydroxypropyl methacrylamide) (HPMA)-7-ethyl-10-hydroxycamptothecin (SN-38) conjugates |
| |
Authors: | Williams Charlotte C Thang San H Hantke Tina Vogel Uwe Seeberger Peter H Tsanaktsidis John Lepenies Bernd |
| |
Affiliation: | CSIRO Materials Science and Engineering, 343 Royal Parade, Parkville, VIC 3052, Australia. |
| |
Abstract: | A series of well‐defined polymer–drug conjugates were prepared in order to modify the physical properties of a known cytotoxic drug, 7‐ethyl‐10‐hydroxycamptothecin (SN‐38), the active metabolite of irinotecan (CPT‐11). Reversible addition–fragmentation chain transfer (RAFT) polymerisation was used to covalently and site‐specifically append a defined N‐(2‐hydroxypropyl)methacrylamide (HPMA) polymer to SN‐38 using a graft‐from process. These poly‐HPMA–SN‐38 conjugates displayed excellent aqueous solubility and stability, whilst retaining the cytotoxic activity of the parent SN‐38. In vitro co‐culture assays containing both cancer and noncancer cell lines demonstrated the specificity of RAFT‐derived poly‐HPMA–SN‐38 conjugates for cancerous cells. The concept of post‐optimisation modification of small‐molecule drugs through a graft‐from polymer conjugation method is introduced. |
| |
Keywords: | camptothecins drug delivery polymer–drug conjugates polymers RAFT polymerization |
本文献已被 PubMed 等数据库收录! |